Literature DB >> 7164773

Primary surgical treatment of carcinoma stage I of the uterine cervix.

V Falk, N Lundgren, L Quarfordt, K Arström.   

Abstract

476 cases of Stage I-IV invasive carcinoma of the uterine cervix were treated at the Gynecology Departments in Karlstad and Orebro in 1965-75. 232 (48.7%) were classified Stage I, 198 (85.3%) of them were treated with primary surgery (57 Stage IA and 141 Stage IB). Thirty-four were given primary radiotherapy because of advanced age or co-existing conditions contra-indicating surgery. Of the 141 patients with primary surgery for Stage IB, squamous epithelial carcinoma was established in 88.7% and adenocarcinoma in 11.3%. Surgery revealed lymph node metastases in 13 (9.2%). Postoperative radiotherapy was given to all patients with lymph node metastases, to 3 patients with tumor thrombi in the parametrial vessels, and to 6 in whom surgery had conceivably not been radical. Urinary tract complications requiring reconstructive surgery occurred in 8 (4.0%). The 5-year survival rate with Stage IB was 91.5%, corrected for intercurrent diseases, 5-year survival was 92.8%. Of the 13 with lymph node metastases, 7 were still alive after 5 years. The 5-year survival rate for those without demonstrable lymph node metastases was 94.5%, corrected 96.0%.

Entities:  

Mesh:

Year:  1982        PMID: 7164773     DOI: 10.3109/00016348209156596

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

1.  Occult advanced cervical cancer.

Authors:  B G Ward; J H Shepherd; J M Monaghan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-04

2.  Elevated expression of thymosin β4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical cancers.

Authors:  Nam Soo Kim; Yun-Jeong Kang; Jin-Ok Jo; Heung Yeol Kim; Young Rim Oh; Young-Ok Kim; Min Hyung Jung; Mee Sun Ock; Hee-Jae Cha
Journal:  Pathol Oncol Res       Date:  2011-01-07       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.